GlassScriptPhysician profile
Jay S Giri
NPI 1881892669
$156,895.32
in general payments reported to CMS, 2019-2025
27 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,478 · 2020: $11K · 2021: $3,001 · 2022: $17K · 2023: $38K · 2024: $48K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $14K · Food and Beverage: $10K · Honoraria: $4,000 · Grant: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,433.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,750.00 |
| Travel and Lodging | $14,442.85 |
| Food and Beverage | $10,042.50 |
| Honoraria | $4,000.00 |
| Grant | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60,177.28 | 2019-2025 | General - Therapies, Clinical Trial Product, Jetstream Sc |
| Inari Medical, INC. | $40,759.44 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $16,676.75 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $8,224.47 | 2019-2022 | |
| Abiomed | $6,239.46 | 2019-2023 | Impella |
| Endovascular Engineering INC. | $5,446.01 | 2025 | Helo Thrombectomy System |
| Novartis Pharmaceuticals Corporation | $4,014.78 | 2025 | |
| Abbott Laboratories | $3,865.86 | 2020-2025 | Navitor, Amplatzer Amulet, Jeti Peripheral Catheter |
| Medtronic Vascular, INC. | $3,138.86 | 2019-2020 | |
| Cordis US Corp. | $2,960.39 | 2023 | Mynx Control |
| Medtronic, INC. | $2,100.73 | 2021-2025 | Symplicity G3, Onyx Frontier, Corevalve Evolut R |
| Angiodynamics, INC. | $1,250.00 | 2024 | Alphavac |
| Shockwave Medical, INC | $470.63 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $323.01 | 2019-2021 | |
| Penumbra, INC. | $297.82 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $150.14 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Artix Mt |
| Terumo Medical Corporation | $130.49 | 2019 | |
| Philips North America LLC | $128.09 | 2023-2025 | Coronary Other |
| Cook Medical LLC | $123.73 | 2019 | |
| Siemens Medical Solutions USA, INC. | $120.11 | 2020 | |
| Cagent Vascular INC | $92.61 | 2021-2025 | Serrantor |
| Cathworks, INC. | $66.88 | 2023-2024 | Ffrangio |
| Teleflex LLC | $37.81 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $37.36 | 2022-2025 | Gore Cardioform Septal Occluder |
| Janssen Scientific Affairs, LLC | $25.20 | 2022 | |
| Btg International INC. | $19.91 | 2019 | |
| Heartflow, INC. | $17.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Giri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.